481 related articles for article (PubMed ID: 17085104)
21. Injectables in the prostate.
Saemi AM; Plante MK
Curr Opin Urol; 2008 Jan; 18(1):28-33. PubMed ID: 18090486
[TBL] [Abstract][Full Text] [Related]
22. Botulinum A toxin urethral sphincter injection in children with nonneurogenic neurogenic bladder.
Mokhless I; Gaafar S; Fouda K; Shafik M; Assem A
J Urol; 2006 Oct; 176(4 Pt 2):1767-70; discussion 1770. PubMed ID: 16945643
[TBL] [Abstract][Full Text] [Related]
23. Botulinum toxin: future developments.
De Ridder D
BJU Int; 2008 Jul; 102 Suppl 1():20-2. PubMed ID: 18665975
[TBL] [Abstract][Full Text] [Related]
24. Injection of botulinum toxin type A in the urethral sphincter to treat lower urinary tract dysfunction: review of indications, techniques and results: 2011 update.
Mahfouz W; Karsenty G; Corcos J
Can J Urol; 2011 Aug; 18(4):5787-95. PubMed ID: 21854710
[TBL] [Abstract][Full Text] [Related]
25. Emerging role of botulinum toxin in the management of voiding dysfunction.
Smith CP; Chancellor MB
J Urol; 2004 Jun; 171(6 Pt 1):2128-37. PubMed ID: 15126771
[TBL] [Abstract][Full Text] [Related]
26. Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland.
Chuang YC; Huang CC; Kang HY; Chiang PH; Demiguel F; Yoshimura N; Chancellor MB
J Urol; 2006 Mar; 175(3 Pt 1):1158-63. PubMed ID: 16469644
[TBL] [Abstract][Full Text] [Related]
27. Botulinum toxin for the lower urinary tract.
Chuang YC; Kuo HC; Chancellor MB
BJU Int; 2010 Apr; 105(8):1046-58. PubMed ID: 22299133
[TBL] [Abstract][Full Text] [Related]
28. Editorial comment on: Mechanisms of prostate atrophy after glandular botulinum neurotoxin type A injection: an experimental study in the rat.
Autorino R
Eur Urol; 2009 Jul; 56(1):140-1. PubMed ID: 18649988
[No Abstract] [Full Text] [Related]
29. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates.
Chuang YC; Chiang PH; Huang CC; Yoshimura N; Chancellor MB
Urology; 2005 Oct; 66(4):775-9. PubMed ID: 16230137
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
31. Intraprostatic and bladder-neck injection of botulinum A toxin in treatment of males with bladder-neck dyssynergia: a pilot study.
Lim SK; Quek PL
Eur Urol; 2008 Mar; 53(3):620-5. PubMed ID: 17950522
[TBL] [Abstract][Full Text] [Related]
32. [Urological applications of botulinum toxins].
Karsenty G; Corcos J; Schurch B
Prog Urol; 2006 Jun; 16(3):263-74. PubMed ID: 16821335
[TBL] [Abstract][Full Text] [Related]
33. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux.
Karsenty G; Elzayat E; Delapparent T; St-Denis B; Lemieux MC; Corcos J
J Urol; 2007 Mar; 177(3):1011-4. PubMed ID: 17296399
[TBL] [Abstract][Full Text] [Related]
34. Botulinum toxin: from life-threatening disease to novel medical therapy.
Mahajan ST; Brubaker L
Am J Obstet Gynecol; 2007 Jan; 196(1):7-15. PubMed ID: 17240220
[TBL] [Abstract][Full Text] [Related]
35. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
[TBL] [Abstract][Full Text] [Related]
36. Novel cutaneous uses for botulinum toxin type A.
Bansal C; Omlin KJ; Hayes CM; Rohrer TE
J Cosmet Dermatol; 2006 Sep; 5(3):268-72. PubMed ID: 17177750
[TBL] [Abstract][Full Text] [Related]
37. [What role does botulinum toxin play in the treatment of benign prostatic hyperplasia?].
Mazdar A; Bedouche A; Zoughari S; Ibrahimi A; Sayegh HE; Iken A; Benslimane L; Nouini Y
Pan Afr Med J; 2016; 24():309. PubMed ID: 28154664
[TBL] [Abstract][Full Text] [Related]
38. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes.
Chuang YC; Tyagi P; Huang CC; Yoshimura N; Wu M; Kaufman J; Chancellor MB
J Urol; 2009 Aug; 182(2):786-92. PubMed ID: 19539320
[TBL] [Abstract][Full Text] [Related]
39. The use of botulinum toxin type A in urological procedures.
Lajiness MJ
Urol Nurs; 2009; 29(6):445-50. PubMed ID: 20088238
[TBL] [Abstract][Full Text] [Related]
40. Botulinum A toxin for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms.
Thomas CA; Chuang YC; Giannantoni A; Chancellor MB
Curr Urol Rep; 2006 Jul; 7(4):266-71. PubMed ID: 16930497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
